CRDF Q4 2020 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$119,255+28.8% YoY

Gross Profit

$119,255100.0% margin

Operating Income

-$6M-5447.9% margin

Net Income

-$7M-5531.9% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-12.3%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$943,835

Balance Sheet

Total Assets

$135M

Total Liabilities

$7M

Stockholders' Equity

$128M

Cash & Equivalents

$131M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$119,255	$92,577	+28.8%
Gross Profit	$119,255	$92,577	+28.8%
Operating Income	-$6M	-$4M	-51.5%
Net Income	-$7M	-$4M	-55.5%